Document Detail


Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice.
MedLine Citation:
PMID:  22460555     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Obesity promotes hypertension, but it is unclear if sex differences exist in obesity-related hypertension. Angiotensin converting enzyme 2 (ACE2) converts angiotensin II (AngII) to angiotensin-(1-7) (Ang-[1-7]), controlling peptide balance. We hypothesized that tissue-specific regulation of ACE2 by high-fat (HF) feeding and sex hormones contributes to sex differences in obesity-hypertension.
METHODS AND RESULTS: HF-fed females gained more body weight and fat mass than males. HF-fed males exhibiting reduced kidney ACE2 activity had increased plasma angiotensin II levels and decreased plasma Ang-(1-7) levels. In contrast, HF-fed females exhibiting elevated adipose ACE2 activity had increased plasma Ang-(1-7) levels. HF-fed males had elevated systolic and diastolic blood pressure that were abolished by losartan. In contrast, HF-fed females did not exhibit increased systolic blood pressure until females were administered the Ang-(1-7) receptor antagonist, D-Ala-Ang-(1-7). Deficiency of ACE2 increased systolic blood pressure in HF-fed males and females, which was abolished by losartan. Ovariectomy of HF-fed female mice reduced adipose ACE2 activity and plasma Ang-(1-7) levels, and promoted obesity-hypertension. Finally, estrogen, but not other sex hormones, increased adipocyte ACE2 mRNA abundance.
CONCLUSIONS: These results demonstrate that tissue-specific regulation of ACE2 by diet and sex hormones contributes to sex differences in obesity-hypertension.
Authors:
Manisha Gupte; Sean E Thatcher; Carine M Boustany-Kari; Robin Shoemaker; Frederique Yiannikouris; Xuan Zhang; Michael Karounos; Lisa A Cassis
Related Documents :
3324715 - Urinary kallikrein excretion can predict the blood pressure response to a single oral d...
9769915 - Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibi...
15823625 - More--moexipril and regression of left ventricle hypertrophy in combination therapy a m...
11058925 - Response of blood pressure to maximum exercise in hypertensive patients under different...
11683775 - The lpl s447x csnp is associated with decreased blood pressure and plasma triglycerides...
6513275 - Tubuloglomerular feedback and interstitial pressure in obstructive nephropathy.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-03-29
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  32     ISSN:  1524-4636     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-17     Completed Date:  2012-07-13     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1392-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3T3-L1 Cells
Adipocytes / enzymology
Adiposity
Angiotensin I / blood
Angiotensin II / blood
Angiotensin II Type 1 Receptor Blockers / pharmacology
Animals
Blood Pressure* / drug effects
Diet, High-Fat
Disease Models, Animal
Estrogens / metabolism
Female
Gene Expression Regulation, Enzymologic
Hypertension / drug therapy,  enzymology,  etiology*,  genetics,  physiopathology
Losartan / pharmacology
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Obesity / complications*,  enzymology,  etiology,  genetics,  physiopathology
Ovariectomy
Peptide Fragments / blood
Peptidyl-Dipeptidase A / deficiency,  genetics,  metabolism*
Progesterone / metabolism
Proto-Oncogene Proteins / antagonists & inhibitors,  metabolism
RNA, Messenger / metabolism
Receptors, G-Protein-Coupled / antagonists & inhibitors,  metabolism
Risk Factors
Sex Factors
Testosterone / metabolism
Time Factors
Weight Gain
Grant Support
ID/Acronym/Agency:
F32HL095281/HL/NHLBI NIH HHS; HL73085/HL/NHLBI NIH HHS; P20 GM103527/GM/NIGMS NIH HHS; P20 GM103527-05/GM/NIGMS NIH HHS; P20RR021954/RR/NCRR NIH HHS; R01 HL073085/HL/NHLBI NIH HHS; R01 HL073085-04/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Estrogens; 0/Peptide Fragments; 0/Proto-Oncogene Proteins; 0/RNA, Messenger; 0/Receptors, G-Protein-Coupled; 0/angiotensin I (1-7); 0/proto-oncogene proteins c-mas-1; 11128-99-7/Angiotensin II; 3XMK78S47O/Testosterone; 4G7DS2Q64Y/Progesterone; 9041-90-1/Angiotensin I; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.17.-/angiotensin converting enzyme 2; JMS50MPO89/Losartan
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipopr...
Next Document:  Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels.